Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioMark Diagnostics Inc. (20B.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.1150-0.0020 (-1.71%)
At close: 03:46PM CET
Advertisement

BioMark Diagnostics Inc.

3851 Shell Road
Suite 130
Richmond, BC V6X 2W2
Canada
604 370 0779
https://www.biomarkdiagnostics.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Rashid Ahmed Maula Bux B.Sc., MBAFounder, CEO, Pres & Director177.05k11.8kN/A
Ms. Guoyu Huang MBAChief Financial Officer70.08k4.43kN/A
Mr. Brian Kai-Ming Cheng B.Sc., M.Sc, M.Sc.Chief Technical Officer & Independent DirectorN/AN/AN/A
Dr. Jeff Haince Ph.D.GM & Chief Scientific OfficerN/AN/AN/A
Neal KaplanChief Financial Officer of USN/AN/AN/A
Dr. Daniel SitarPrincipal Scientific AdvisorN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Corporate Governance

BioMark Diagnostics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement